Japanese Government Procurement

Nagoya City University1) Nivolumab (Genetical Recombination) 240mg 24ml 1vial 217vial 2) Infliximab (Genetical recombination) 100mg 1vial 951vial 3) Pembrolizumab (Genetical Recombination) 100mg 4ml 1vial 175vial 4) Ustekinumab (Genetical Recombination) 45mg 1syringe 119syringe 5) Aflibercept (Genetical Recombination)...

Japanese

Publishing date Feb 13, 2020
Procurement entity Nagoya City University（Aichi）
Classification
0004 Medical & Pharmaceutical Products
Summary of notice Summary
(1) Nature and quantity of the product to be purchased:
1) Nivolumab (Genetical Recombination)
240mg 24ml 1vial 217vial
2) Infliximab (Genetical recombination)
100mg 1vial 951vial
3) Pembrolizumab (Genetical Recombination)
100mg 4ml 1vial 175vial
4) Ustekinumab (Genetical Recombination)
45mg 1syringe 119syringe
5) Aflibercept (Genetical Recombination)
40mg 1ml 1vial 301vial
6) Lenalidomide Hydrate
5mg 40capsule 93capsule
7) Emicizumab (Genetical Recombination)
90mg 0.6ml 1vial 35vial
8) Bevacizumab (Genetical Recombination)
16ml 1vial 207vial
(2) Deadline for the submission of application forms and relevant
documents for qualification:
February 26, 2020 at 10:00 a.m.
(3) Deadline for the submission of tenders:
March 25, 2020 at 10:00 a.m.
(tenders submitted by mail are due by March 24, 2020 at 5:00 p.m.)
(4) Contact point:
Medical Science & hospital Administration Department, Administration
Division, of Nagoya City University Hospital
1, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya-city, 467-8602 Japan